NovaBridge Biosciences reported year-end 2025 results and advanced two mid-stage assets: givastomig, a CLDN18.2 x 4-1BB bispecific antibody in first-line metastatic gastric cancer, and VIS-101, a VEGF-A x Ang-2 inhibitor in wet AMD. The company disclosed compelling Phase 1b expansion data for givastomig, potential FDA accelerated approval eligibility for a defined first-line subset of gastroesophageal cancer, positive Phase 2a signals for VIS-101, and a cash runway through 2028 supported by $210.8 million on hand.
The strategic pivot is clear: NovaBridge has rebuilt itself as a hub-and-spoke development platform, concentrating capital and executive talent on two programs with credible differentiation in crowded markets. That choice raises a pivotal question for senior commercial and medical leaders: can the company translate promising, early data into registrational momentum and real-world adoption in indications where standards have moved materially over the past three years?
Oncology first. Givastomig’s 75% objective response rate and a 16.9-month median progression-free survival in Phase 1b, alongside favorable tolerability in combination with immunochemotherapy, set an assertive bar for a CLDN18.2-directed agent that also conditionally activates 4-1BB in the tumor microenvironment. If sustained in larger studies, the profile could push past monofunctional CLDN18.2 antibodies by pairing tumor engagement with localized T-cell costimulation, a long-sought mechanism undermined historically by systemic 4-1BB toxicity. The FDA’s indication that an accelerated approval pathway may be viable in first-line, HER2-negative, CLDN18.2-positive, PD-L1–positive disease positions NovaBridge to design a registrational strategy as early as late 2026. That path will hinge on a validated CLDN18.2 diagnostic, clear patient selection criteria, and an agreed-upon confirmatory OS strategy in a frontline setting where chemo plus PD-1 is entrenched. For payers and HCPs, the question will be whether a biomarker-driven, IO-chemotherapy backbone plus bispecific can deliver enough incremental benefit to justify complexity and cost. For competitors across monoclonals, ADCs, and cell therapies aiming at CLDN18.2, the durability and safety of a 4-1BB–enabled approach will be the focal comparator, even if only via cross-trial context in the near term.
In ophthalmology, VIS-101’s Phase 2a data showing rapid vision gains, meaningful anatomic improvements, and a dosing-free interval extending to four to six months in a substantial fraction of patients speaks to the market’s primary unmet need: durability. Yet the bar has risen. Faricimab, with dual Ang-2/VEGF targeting, and aflibercept 8 mg have reset expectations for Q12–Q16 week regimens in the U.S. and EU. VIS-101 will need to prove superiority or at least noninferior durability with fewer injections, clean safety, and predictable responder identification. Given retina’s buy-and-bill economics and step therapy norms, pricing and dosing flexibility will matter as much as marginal efficacy gains. A Phase 2b in the second half of 2026, followed by a global Phase 3 in 2027, points to a capital-intensive path where asset-centric financing via NovaBridge’s Visara subsidiary and regional partnerships could be decisive for speed and reach.
The company’s strengthened board and leadership, ophthalmology and oncology expertise, and a cash runway through 2028 provide time to prosecute these plans, but not to single-handedly complete global registrational programs and build two commercial infrastructures. Expect partnering, co-development, or creative financing to bridge pivotal execution and launch readiness. The broader trendline is familiar: focused platforms concentrating on de-risked biology, biomarker-defined oncology, and durability-led retina entrants, financed through modular subsidiaries and regional alliances rather than monolithic balance sheets.
What happens next will be defined by design discipline. In gastric cancer, can NovaBridge lock a pragmatic accelerated approval design with an embedded confirmatory plan and companion diagnostic, and will the signal hold in PD-L1–negative populations that represent a large clinical reality? In wet AMD, can VIS-101 credibly outlast today’s dosing intervals in head-to-head settings while clearing the access hurdles of a late entrant? The answers will determine whether NovaBridge remains a sharp development engine or graduates into a commercial contender.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
